After a six-month review, the FDA has updated the indication for the injectable macular degeneration drug ranibizumab (Lucentis) for the treatment of retinal vein occlusion. The approval was based on the results of two studies that pooled data from 789 patients with macular edema after central and branch retinal vein occlusion, comparing results using 0.3 mg and 0.5 mg ranibizumab injections against placebo with best-corrected visual acuity ratings after six months.

Read the full story here ^[1] on MedPage Today.